Martin S. Polinsky

Belatacept and Long-Term Outcomes in Kidney Transplantation

Flavio Vincenti, Lionel Rostaing, J.M. Boria Grinyo et al. · New England Journal of Medicine · 2016 · 738 citations · Full text

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

Francesco Paolo Schena, M.D. Pascoe, Josefina Alberú et al. · Transplantation · 2009 · 574 citations

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

Josefina Alberú, M.D. Pascoe, Josep M. Campistol et al. · Transplantation · 2011 · 221 citations

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study

Antoine Dürrbach, José Medina‐Pestana, Sander Florman et al. · American Journal of Transplantation · 2016 · 152 citations · Full text

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

Robert A. Bray, Howard M. Gebel, Robert Townsend et al. · American Journal of Transplantation · 2018 · 126 citations · Full text

Transplantation Medicine, Immunology, Donor-specific Antibodies +19